RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral small-molecule GLP-1 therapy, backed by an oversubscribed $100 million ...

San Francisco-based Braveheart Bio, a clinical-stage biotech company, has appointed Emil deGoma, MD, as its chief medical officer. Dr. deGoma, a cardiologist, joins Braveheart Bio from Tourmaline Bio, ...

Shionogi has struck a deal to take full control of its sleep disorder joint venture, agreeing to pay Apnimed $100 million upfront for its partner’s half of the business. Shionogi called the joint ...

About the author: Nilesh Kumar is head of biotech private investments at Wellington Management. As pharmaceutical companies raced to develop a Covid-19 vaccine in 2020, the biotech industry boomed.

Claflin University held a groundbreaking ceremony for the school's new Center for Biotechnology and Innovation on March 20.